Pharmacological intervention: The antiobesity approach

European Journal of Clinical Investigation, Supplement

Volumn 28, Issue 2, 1998, Pages 27-30

  Rissanen, A ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Obesity; Pharmacotherapy; Type II diabetes

Indexed keywords

DEXFENFLURAMINE; HEMOGLOBIN A1C; PLACEBO; SIBUTRAMINE; TETRAHYDROLIPSTATIN;

CONFERENCE PAPER; DRUG EFFICACY; HUMAN; IMPAIRED GLUCOSE TOLERANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; WEIGHT REDUCTION;

EID: 0031656951     PISSN: 0960135X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.1998.0280s2027.x     Document Type: Conference Paper

References (25)

1. Newburgh LH. Control of hyperglycaemia of obese 'diabetics' by weight reduction. Ann Intern Med 1942; 17: 935-72.
2. Liu GC, Coulston AM, Lardinois CK, Hollenbeck CB, Moore JG, Reaven GM. Moderate weight loss and sulphonylurea treatment of non insulin-dependent diabetes mellitus. Arch Intern Med 1985; 145: 665-9.
3. Wing RR, Koeske R, Epstein LH, Nowalk MP, Gouding W, Becker D. Long-term effects of modest weight loss in type 2 diabetic patients. Arch Intern Med 1987; 147: 1749-53.
4. Goldstein DJ. Beneficial health effects of modest weight loss. Int J Obesity 1992; 16: 397-115.
5. Silverstone T. Appetite suppressants: A review. Drugs 1992; 43: 820-34.
6. The National Task Force on the Prevention and Treatment of Obesity. Long-term pharmacotherapy in the management of obesity. JAMA 1996; 276: 1907-15.
7. Guy-Grand B, Apfelbaum M, Crepaldi G, Gries A, Lefebre P, Turner P. International trial of long-term dexfenfluramine in obesity. Lancet 1989; ii: 1142-5.
8. Sjöström L, Rissanen A, Andersson T, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight gain in obese patients. Lancet 1998; 352: 167-172.
9. Jones SP, Smith IG, Kelly F, Gray JA. Long-term weight loss with sibutramine. Int J Obesity 1995; 19(Suppl. 2): 41.
10. Franz MJ, Horton ES, Bantle JP et al. Nutrition principles for the management of diabetes and related complications. Diabetes Care 1994; 17: 242-6.
11. Maggio CA, Pi-Sunyer FX. The prevention and treatment of obesity. Application to type 2 diabetes. Diabetes Care 1997; 20: 1744-65.
12. Pestell RG, Crock PA, Ward GM, Alford FP, Best JD. Fenfluramine increases insulin action in patients with NIDDM. Diabetes Care 1989; 12: 252-8.
13. Scheen AJ, Paolisso G, Salvatore T, Lefebre PJ. Improvement of insulin induced glucose disposal in obese patients with NIDDM after 1 week treatments with d-fenfluramine. Diabetes Care 1991; 14: 325-32.
14. Verdy M, Carbonneau L, Verdy I, Belanger R, Boite E, Chiasson J-L. Fenfluramine in the treatment of non insulin-dependent diabetics: hypoglycaemic versus anorectic effect. Int J Obesity 1983; 7: 289-97.
15. Chow C-C, Ko GTC, Tsang LWW, Veung VTE, Chan JCN, Cockram CS. Dexfenfluramine in obese Chinese NIDDM patients. Diabetes Care 1997; 20: 1122-7.
16. Stewart GO, Stein GR, Davies TME, Findlater T. Dexfenfluramine in type 2 diabetes: effect on weight and diabetes control. Med J Aust 1993; 158: 167-9.
17. Marks SJ, Moore NR, Clark ML, Strauss BJG, Hockaday TDR. Reduction of visceral adipose tissue and improvement of metabolic indices: effect of dexfenfluramine in NIDDM. Obesity Res 1996; 4: 1-9.
18. Willey KA, Molyneaux LM, Overland JE, Yue DK. The effects of dexfenfluramine on blood glucose control in patients with type 2 diabetes. Diabet Med 1992; 9: 341-5.
19. Willey KA, Molyneaux LM, Yue DK. Obese patients with type 2 diabetes poorly controlled by insulin and metformin: effects of adjunctive dexfenfluramine therapy on glycaemic control. Diabet Med 1994; 11: 701-1.
20. Griffiths J, Byrnes AE, Frost G et al. Sibutramine in the treatment of overweight non-insulin-dependent diabetics. Int J Obesity 1995; 19(Suppl. 2): 41.
21. Shepherd G, Fitchet M, Kelly F. Sibutramine: a metaanalysis of the change in fasting plasma glucose in patients with a high baseline fasting value (> 5·5 mmol/l). Int J Obesity 1997; 21(Suppl. 2): S54.
22. Tauber-Lassen E, Damsbo P, Henriksen JE, Palmvig B, Beck-Nielsen H. Improvement of glycaemic control and weight loss in type 2 (non insulin-dependent) diabetics after one year of dexfenfluramine treatment. Diabetologia 1990; 33: A124.
23. Hollander P. A 57-week study of orlistat in the treatment of obese patients with NIDDM. Diabetes 1997; 46(Suppl. 1): 55A.
24. Rissanen A. Orlistat-induced weight loss improves response to oral glucose tolerance testing. Int J Obesity 1998; 22(Suppl. 2): in press.
25. Wauters M, Peiffer F, Gubbels N, et al. Visceral fat decreases after six months treatment with sibutramine in obese subjects. Int J Obesity 1997; 21(Suppl. 2): 55.